INTRODUCTION
============

Chronic kidney disease (CKD) is associated with reduced physical function, independent of age, gender and traditional vascular and cardiovascular risk factors \[[@sfy080-B1]\]. Physical function refers to an individual's functional ability to perform activities of daily living (ADLs), instrumental activities and other discretionary activities \[[@sfy080-B2]\]. Furthermore, reduced exercise capacity has been shown to be a strong predictor of survival among ambulatory patients with end-stage renal disease (ESRD) \[[@sfy080-B3]\]. This is important since a reduction in physical function is not exclusive to haemodialysis patients but has also been demonstrated in patients prior to requiring renal replacement therapy (RRT) \[[@sfy080-B4]\]. When compared with age-matched controls, patients with CKD have greater levels of impairment across all aspects of physical function \[[@sfy080-B5]\]. Roshanravan *et al*. \[[@sfy080-B6]\] reported an association between reduced lower limb function (including gait speed and timed up and go) and increased risk of mortality among patients with CKD Stages 2--4. However, upper limb function assessed using grip strength was not shown to be a significant predictor of mortality.

Performing objective tests of physical performance, such as those reported by Roshanravan *et al.* \[[@sfy080-B6]\], may not always be clinically applicable due to time and space constraints, and the need for an observer to record measurements. In contrast, self-reported measures may offer a more practical and cost-effective way of assessing physical function. Patient-reported outcome measures have the potential to assess the effect of declining physical function on the ability to participate in ADLs, which is often the prominent concern of patients \[[@sfy080-B2]\]. The Duke Activity Status Index (DASI) is a short 12-item validated patient-reported outcome measure designed to assess functional capacity via an individual's ability to participate in life activities \[[@sfy080-B7]\]. The DASI was originally designed to assess physical function and aspects of quality of life in patients with cardiovascular disease \[[@sfy080-B7]\] but has since been widely used in several clinical populations. This includes patients with CKD not requiring RRT, where the DASI has been shown to be reliable and have high agreement with the gold standard measure of cardiorespiratory fitness \[[@sfy080-B8]\]. Alternative measures of self-reported physical function, such as the Human Activity Profile (HAP) and 36-item Short Form Health Survey (SF-36), have been shown to correlate well with performance measures in patients requiring dialysis treatment \[[@sfy080-B9]\], but to our knowledge they have not been validated as a measure of physical function in non-dialysis CKD patients. Furthermore, the HAP is often criticized for its length (94 items) and the time required to complete it \[[@sfy080-B10]\]. When considering the choice of outcome measures, certain factors should be taken into consideration, including patient burden, accuracy of the measure, cost and ability to implement the measure into routine practice \[[@sfy080-B2]\]. The DASI is quick to complete, has been shown to be an accurate measure in the target population and has the potential to be distributed in large numbers and assess the physical function of most patients at routine clinic appointments. However, currently it is unknown if a self-reported measure of physical function incorporating activities requiring both upper and lower body strength is associated with adverse outcomes in CKD patients.

Physical inactivity may contribute to reduced levels of physical function and exercise capacity in CKD, although the nature of the relationship is likely to be bidirectional. Physical activity refers to any movement produced by the skeletal muscles that increases energy expenditure above resting \[[@sfy080-B2]\], and is strikingly low among CKD patients \[[@sfy080-B11]\]. Evidence suggests that despite guideline recommendations \[[@sfy080-B9], [@sfy080-B12]\], almost 60% of patients with CKD are insufficiently active to experience health benefits \[[@sfy080-B13]\]. Beddhu *et al.* \[[@sfy080-B13]\] conducted a prospective follow-up analysis of physical activity and mortality among patients with non-CKD and CKD patients and reported that within the CKD cohort, achieving physical activity goals set by international guidelines was associated with a 56% reduction in mortality risk over a 7-year follow-up. Patients with CKD often describe walking as their preferred form of physical activity \[[@sfy080-B14]\]; regular walking has been shown to be cardioprotective \[[@sfy080-B15]\] and is associated with a reduced risk of RRT \[[@sfy080-B16]\] and all-cause mortality among CKD patients \[[@sfy080-B16]\]. Furthermore, walking speed has been shown to predict a decline in physical function, hospitalization and all-cause mortality in ESRD \[[@sfy080-B17]\]. However, the association between walking behaviours and survival has not been explored previously among a UK CKD population. Based on the available literature, we hypothesize that better levels of self-reported physical function (assessed by the DASI and self-reported walking pace) and greater volume of weekly walking will be associated with a reduced risk of mortality among non-dialysis CKD.

The aim of this study was to investigate if self-reported physical function and walking behaviours are associated with survival among patients with CKD not requiring RRT.

MATERIALS AND METHODS
=====================

We analysed data from the QCKD study (Physical activity opinions in kidney patients; ISRCTN 87066351), a prospective observational mixed methods study of physical activity in patients with CKD Stages 1--5 not requiring RRT. Participants were recruited from a single-centre, secondary-care National Health Service outpatient unit within the UK between September 2012 and June 2013.

Recruitment and inclusion
-------------------------

Participants were invited to participate by a researcher in the outpatient clinic while awaiting their appointment. All patients \>18 years of age with CKD Stages 1--5 not requiring RRT were eligible to participate. During the recruitment period we visited 54 outpatient clinics and approached 563 patients. This study was approved by the National Research Ethics Service Committee East Midlands--Northampton on 13 June 2012.

Procedures
----------

Upon entry to the study, participants were asked to complete a survey pack that included questionnaires assessing self-reported levels of physical function and physical activity. Demographic and clinical data including age, gender, ethnicity, estimated glomerular filtration rate (eGFR; Modification of Diet in Renal Disease equation), haemoglobin and comorbidities were obtained from patient medical records. The extraction of clinical data was performed in temporal proximity to questionnaire completion. Written consent was obtained prior to accessing medical records.

Self-reported physical function
-------------------------------

Physical function was assessed via self-reports using the DASI. This is a brief 12-item questionnaire that enquires about an individual's capability to complete ADLs \[[@sfy080-B10]\]. Each activity is weighted with a metabolic equivalent of tasks (METs) value, which is then summed to produce a continuous measure ranging from 0 to 58.2. The DASI has previously been used in patients with CKD not requiring RRT and has been shown to be both a valid and reliable predictor of exercise capacity \[[@sfy080-B8]\]. A higher DASI score is associated with better physical functioning.

Self-reported walking behaviours
--------------------------------

The General Practice Physical Activity Questionnaire (GPPAQ) is a screening tool used to classify individuals to one of four physical activity levels: inactive, moderately inactive, moderately active or active \[[@sfy080-B18]\]. However, certain subcategories within the questionnaire such as walking, gardening, housework and walking pace are not included in the classification system. Instead, this relies on employment status, hours of gym work and cycling. As the majority of participants in this study were of retirement age, and walking is often cited as the most common form of physical activity among CKD patients, we extracted hours of walking and walking pace from the GPPAQ. As part of the GPPAQ, participants were asked to report the number of hours spent walking per week, including walking to work, shopping and walking for pleasure. Responses were recorded categorically: none, some but \<1, 1--3 or ≥3 h. In addition, participants were asked to self-report their walking pace as slow (\<3 mph), steady, brisk or fast (\>4 mph).

Outcome assessment
------------------

Mortality data were extracted from an electronic patient medical record used for renal patients in September 2016. Patient records are routinely accessed and updated by the clinical team. Time zero in the survival models was taken as the point where patients were consented to the study and completed the survey questions. Patients were right censored if they had not experienced the event (death) at the time of data extraction (the end of study); RRT was considered a competing risk event.

STATISTICAL ANALYSIS
====================

Descriptive statistics were summarized as median \[interquartile range (IQR)\] for continuous variables and percentages for categorical variables. Categorical variables, including hours of walking (0, \<1, 1--3 and ≥3 h) and self-reported walking pace \[slow (\<3 mph), steady, brisk and fast (\>4 mph)\] were extracted from the GPPAQ. Due to the small number of participants reporting brisk or fast walking, the categories were merged for analysis to create two walking pace groups: \<3 and ≥3 mph.

The main outcome of interest was mortality after study enrolment. We estimated the cumulative incidence function and tested differences across categorical variables using a modified log-rank test \[[@sfy080-B19]\]. A receiver operating characteristics (ROC) curve was constructed to plot the performance of the DASI continuous scores as a binary classifier for survival in order to identify a potential clinical marker for risk stratification. Sensitivity and specificity analyses were performed to identify the best cut-off score to predict mortality. We fitted Fine and Gray \[[@sfy080-B20]\] models to examine the association between physical function, hours of walking per week, walking pace and mortality in both unadjusted and adjusted models considering the competing risk of RRT; the proportional subhazards assumption was tested using Schoenfeld residuals. Models were constructed to explore DASI scores as both binary and continuous variables. The models were then adjusted to control for the following covariates: age, gender, ethnicity, eGFR, haemoglobin, diabetes mellitus, hypertension and ischaemic heart disease. In addition, four sensitivity analyses were conducted: (i) using a modified inclusion criterion of CKD, that is, including only participants with an eGFR \<60 mL/min/1.73 m^2^; (ii) removing deaths within the first 6 months to reduce the potential of reverse causation; (iii) imputing missing data to generate 10 imputed datasets with results combined using Rubin's rules \[[@sfy080-B21]\] and (iv) to estimate mortality hazard ratios (HRs) for variables of interest a standard Cox regression model was conducted, where competing events were censored.

Assuming a binary variable (high versus low DASI score or walking pace) with roughly equal numbers within each category, a 90% survival in one group and 70% survival in the other group, a significance of 0.05 and a log-rank test power of 90%, an overall sample size of at least 178 participants was required.

Statistical analyses were performed using SPSS Statistics for Windows, version 22 (IBM, Armonk, NY, USA) and Stata version 13 (StataCorp, College Station, TX, USA) \[[@sfy080-B22]\]. Statistical significance was accepted as a P-value \<0.05 and results are reported with 95% confidence intervals (CIs) unless stated otherwise.

RESULTS
=======

Data from 450 participants were available for analysis ([Figure 1](#sfy080-F1){ref-type="fig"} shows the flow of participants through the study). Follow-up data were obtained covering a median of 43 (IQR 42--45) months. During the follow-up period, 74 (16.4%) deaths occurred and 101 (22.4%) patients started RRT. The rate (per 1000 person-years) was 58 for mortality and 79 for starting RRT. No patients were lost to follow-up. Missing data for all variables of interest were \<5%. Participant characteristics are detailed in [Table 1](#sfy080-T1){ref-type="table"}. Cumulative incidence curves for self-reported physical function, walking pace and hours of walking are shown in [Figure 2](#sfy080-F2){ref-type="fig"}. Table 1.Baseline characteristicsCharacteristicsTotal (*N* = 450)Event-free (*n* = 275)RRT (*n* = 101)Deceased (*n* = 74)Age (years), median (IQR)62 (48--75)61 (45--73)57 (48--68)79 (68--83)Gender (male), *n* (%)258 (57)147 (54)60 (59)51 (69)Ethnicity (white), *n* (%)360 (80)226 (82)63 (62)71 (96)eGFR (mL/min/1.73 m^2^), median, (IQR)29 (19--54)43 (27--74)16 (11--19)23 (17--34)Haemoglobin (g/L), median (IQR)122 (108--135)129 (115--139)111 (102--123)114 (111--126)Diabetes, *n* (%)121 (27)62 (23)32 (32)27 (37)Hypertension, *n* (%)247 (55)128 (47)77 (76)42 (57)Ischaemic heart disease, *n* (%)82 (18.2)36 (13)18 (18)28 (38)DASI summed METs, median (IQR)35.7 (18.95--50.70)42.7 (23.45--58.2)31.45 (15.45--50.2)18.48 (9.95--28.7)Walking hours (weekly), *n* (%)  086 (19)32 (12)19 (19)35 (47) \<1113 (25)72 (26)25 (25)16 (22) 1--3116 (26)83 (30)25 (25)8 (11) ≥3122 (27)81 (30)30 (30)11 (15) Missing13 (3)7 (3)2 (2)4 (5)Walking pace \<3 mph188 (42)86 (31)45 (45)57 (77) ≥3 mph243 (54)177 (64)52 (52)14 (19) Missing19 (4)12 (4)4 (4)3 (4)
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Associations between physical function and survival
---------------------------------------------------

Data on self-reported physical function were available for 450 participants, 74 of whom died over the follow-up period. The ROC curve showed that a DASI score of 19.2 predicted mortality with 60% sensitivity and 77% specificity \[area under the curve 0.76 (95% CI 0.71--0.81), P \< 0.001\]. The rate (per 1000 person-years) was 22 for patients scoring \>19.2 and 36 for patients scoring ≤19.2. After adjustment for age, gender, ethnicity, eGFR, haemoglobin, hypertension, diabetes mellitus and ischaemic heart disease, participants with a DASI score \>19.2 had a lower incidence of death \[subdistribution hazard ratio (SHR) 0.51 (95% CI 0.30--0.88)\] ([Table 2](#sfy080-T2){ref-type="table"}). When used continuously, a 1-unit higher DASI was associated with a 3% reduction in mortality \[SHR 0.97 (95% CI 0.95--0.99), P = 0.004\] ([Table 2](#sfy080-T2){ref-type="table"}). Table 2.Competing risk analysis for mortality (*n* = 450)MeasuresCrude SHRs (95% CI)Adjusted SHRs (95% CI)DASI (0--58.2) (per 1-unit increase)0.95 (0.94--0.97)[\*\*](#tblfn2){ref-type="table-fn"}0.97 (0.95--0.99)[\*\*](#tblfn2){ref-type="table-fn"}DASI (\>19.2 summed METs versus ≤19.2)0.24 (0.15--0.38)[\*\*](#tblfn2){ref-type="table-fn"}0.51 (0.30--0.88)[\*](#tblfn2){ref-type="table-fn"}Walking hours (weekly) (reference 0 h) \<10.30 (0.17--0.54)[\*\*](#tblfn2){ref-type="table-fn"}0.48 (0.26--0.90)[\*](#tblfn2){ref-type="table-fn"} 1--30.14 (0.06--0.30)[\*\*](#tblfn2){ref-type="table-fn"}0.25 (0.11--0.57)[\*\*](#tblfn2){ref-type="table-fn"} ≥30.18 (0.09--0.36)[\*\*](#tblfn2){ref-type="table-fn"}0.48 (0.23--0.80)[\*](#tblfn2){ref-type="table-fn"}Walking pace (reference \<3 mph) ≥3 mph0.17 (0.09--0.30)[\*\*](#tblfn2){ref-type="table-fn"}0.37 (0.20--0.71)[\*\*](#tblfn2){ref-type="table-fn"}[^2][^3]

Associations between hours of walking and survival
--------------------------------------------------

Data on the number of hours walked were available for 437 participants, 70 of whom died over the follow-up period. Compared with 0 h weekly, any amount of walking (\<1, 1--3 and ≥3 h) was associated with a reduced risk of mortality before and after adjustment ([Table 2](#sfy080-T2){ref-type="table"}).

Associations between walking pace and survival
----------------------------------------------

Self-reported walking pace data were available for 431 participants, 71 of whom died during the follow-up period. A self-reported walking pace ≥3 mph was associated with a 63% lower risk of death \[SHR 0.37 (95% CI 0.20--0.71)\] ([Table 2](#sfy080-T2){ref-type="table"}).

SENSITIVITY ANALYSES
====================

Sensitivity analyses restricted to patients with an eGFR \>60 mL/min/1.73 m^2^, removing death in the first 6 months, imputing missing values or using Cox HRs rather than a competing risk model largely demonstrated a consistent pattern of results, particularly for the DASI as a continuous score and walking pace, with associations seen with mortality across all models ([Table 3](#sfy080-T3){ref-type="table"}). Table 3.Sensitivity analyses1234MeasuresAdjusted SHRs (95% CI)P-valueAdjusted SHRs (95% CI)P-valueAdjusted SHRs (95% CI)P-valueAdjusted HRs (95% CI)P-valueDASI (per 1-unit increase)0.97 (0.95--0.99)[\*\*](#tblfn8){ref-type="table-fn"}0.0030.97 (0.95--1.00)[\*\*](#tblfn8){ref-type="table-fn"}0.0160.97 (0.95--0.99)[\*\*](#tblfn8){ref-type="table-fn"}0.0110.97 (0.95--0.99)[\*](#tblfn8){ref-type="table-fn"}0.006DASI (\>19.2 summed METs versus ≤19.2)0.47 (0.27--0.83)[\*\*](#tblfn8){ref-type="table-fn"}0.0090.56 (0.32--1.01)0.0540.53 (0.30--0.92)[\*](#tblfn8){ref-type="table-fn"}0.0230.52 (0.30--0.90)[\*](#tblfn8){ref-type="table-fn"}0.019Walking hours (weekly) (reference 0 h) \<10.43 (0.22--0.82)[\*\*](#tblfn8){ref-type="table-fn"}0.010.55 (0.29--1.05)0.0680.57 (0.30--1.10)0.0740.54 (0.29--1.00)[\*](#tblfn8){ref-type="table-fn"}0.049 1--30.24 (0.11--0.55)[\*\*](#tblfn8){ref-type="table-fn"}0.0010.60 (0.28--1.27)[\*\*](#tblfn8){ref-type="table-fn"}0.0020.30 (0.13--0.68)[\*\*](#tblfn8){ref-type="table-fn"}0.0040.28 (0.12--0.62)[\*](#tblfn8){ref-type="table-fn"}0.002 ≥30.44 (0.21--0.94)[\*](#tblfn8){ref-type="table-fn"}0.0340.23 (0.09--0.58)0.180.54 (0.27--1.09)0.0830.48 (0.23--1.00)[\*](#tblfn8){ref-type="table-fn"}0.051Walking pace (reference \<3 mph) ≥3 mph0.35 (0.18--0.68)[\*\*](#tblfn8){ref-type="table-fn"}0.0020.37 (0.19--0.74)[\*\*](#tblfn8){ref-type="table-fn"}0.0050.40 (0.20--0.78)[\*\*](#tblfn8){ref-type="table-fn"}0.0090.38 (0.20--0.72)[\*](#tblfn8){ref-type="table-fn"}0.003[^4][^5][^6][^7][^8][^9]

DISCUSSION
==========

Objective measures of physical performance have been shown to associate with an increased risk of mortality \[[@sfy080-B23]\]. This study aimed to explore whether self-reported measures of physical function and walking behaviours are associated with survival among a CKD cohort not requiring RRT. We found that self-reported physical function is independently associated with mortality. Specifically, when using competing risk models for RRT, self-reported levels of physical function indicated by a DASI score \>19.2 and walking pace \>3 mph were associated with a 49 and 63% reduced risk of mortality. This suggests that the DASI score or self-reported walking pace may be a useful prognostic factor when used alongside clinical and other known risk markers for identifying patients who are at risk for adverse outcomes. Using an equation previously validated in this population \[[@sfy080-B8]\], a DASI score of 19.2 equates to an estimated peak oxygen consumption (VO~2peak~) score of 17.86 mL/min/kg, similar to the median cut-off of 17.5 mL/min/kg reported by Sietsema *et al.* \[[@sfy080-B3]\] that predicted survival in a relatively healthy subset of ESRD patients. Baseline VO~2peak~ scores were determined by a standardized cycle ergometry exercise protocol and were shown to significantly contribute to an explanatory model relating clinical variables to mortality \[[@sfy080-B3]\]. The DASI is a validated, quick and simple measure of exercise capacity that has been widely utilized within CKD research studies \[[@sfy080-B24], [@sfy080-B25]\] and could be incorporated relatively easily into routine clinical assessment.

Furthermore, the benefits of regular walking among patients with CKD are well documented \[[@sfy080-B26]\]. To our knowledge, this is the first study to report the association between walking behaviours and survival in a UK CKD cohort. The results of this study indicate that participants reporting 1--3 h of walking per week had the greatest reduction in risk of mortality. Previous research from a large observational study conducted in China indicated that walking frequency was associated with survival among patients with CKD Stages 3--5 \[[@sfy080-B16]\], independent of age, eGFR and comorbidities. The authors reported a relationship between walking frequency and lower mortality, however, they did not specifically state the relationship between walking duration and mortality. In our study, any reported walking activity was associated with a reduction in mortality, with no clear evidence of a dose--response relationship. The lack of a clear linear dose response may be due to uncaptured confounders such as exercise intensity and other known comorbidities, for example, peripheral vascular disease and cerebrovascular disease. The cross-sectional nature of the current study precludes our ability to draw any conclusions regarding the dose--response relationship between physical activity and mortality in patients with CKD. However, a meta-analysis of 22 studies undertaken in the general population showed that walking 2.5 h/week was associated with a 19% reduction in all-cause mortality risk, whereas walking 7 h/week was associated with an increase of 24% \[[@sfy080-B27]\]. This indicated that the greatest benefits to health may be found when encouraging patients to move from sedentary to low levels of activity, although further health benefits were still accrued from additional activity in patients reporting greater levels of physical activity \[[@sfy080-B28]\]. Further work, including walking frequency, duration and intensity, is required to explore the dose--response relationship in patients with CKD.

Gait speed is known to be associated with survival in older adults \[[@sfy080-B29]\] and patients with CKD \[[@sfy080-B6]\]. However, objective measures of gait speed are not readily available in a clinical setting. Therefore self-reported measures of walking pace may offer an alternative that is quick and simple to complete and could be easily implemented into routine clinical assessment. Recent evidence has suggested that self-reported walking pace may provide a good surrogate measure of walking speed when direct measurement is unavailable \[[@sfy080-B30]\], while also being associated with cardiorespiratory fitness and mortality within the general population \[[@sfy080-B31]\]. Our results suggest that patients who reported a walking speed ≥3 mph had a reduced risk of mortality. Indeed, the reduction in risk for walking pace was more pronounced than the threshold of physical function (DASI score 19.2) derived from this study, suggesting a simple self-reported walking pace question could also be used to predict future morality risk in CKD patients. Furthermore, in somewhat of a contradiction to the relationship between physical activity and mortality, the association between walking pace and risk of mortality has been shown to be linear. Reasons for this are not fully understood, however, faster walking pace may be an indicator of vitality and multiple organ system function, thus offering a proxy measure of overall health \[[@sfy080-B29]\]. Roshanravan *et al.* \[[@sfy080-B6]\] demonstrated in fully adjusted models that for every 1-s increase on the timed up and go, the risk of death increased by 8%. Slowness is also a defining characteristic of frailty syndrome, which has been shown to increase the risk of mortality \[[@sfy080-B32]\]. However, further work is now required to determine if interventions targeting walking pace are associated with improved outcomes in CKD patients at risk of adverse events.

To our knowledge this is the largest CKD cohort utilized to investigate the association between self-reported physical function and survival. However, this study is not without its limitations. Due to the observational study design, caution should be exercised when assigning a causal relationship between self-reported physical function and walking behaviours and an increased risk of mortality. Moreover, although we adjusted for some factors (e.g. age, sex, haemoglobin), residual confounding or confounding by unmeasured factors remains a possibility. Data regarding causes of death were not obtainable, and as such we were limited in our ability to perform additional analyses regarding cardiovascular mortalities, which would have been of interest. Furthermore, it remains unclear from this study and the literature if positive changes to walking behaviour and physical function are associated with improved rates of survival. Previous research has demonstrated that both physical function and physical activity in patients with CKD can be successfully targeted via exercise \[[@sfy080-B33]\] and behavioural intervention \[[@sfy080-B34]\]. Therefore further longitudinal and interventional studies are required to assess the rate at which function declines and how this associates with adverse outcomes, to investigate the effect of increasing levels of physical activity and improving physical function on adverse events and to determine the optimal dose response for walking with regards to frequency, duration and intensity associated with survival. In addition, as with all self-reported data, there may be tendencies for participants to over- or underestimate physical capabilities and levels of physical activity. However, in the absence of objective assessment, we have shown that self-reported measures can be incorporated into routine clinical assessment and help to identify patients at risk of adverse events.

Self-reported physical function, hours of walking and walking pace are independent predictors of mortality in non-dialysis CKD patients. This suggests that the DASI and self-reported measures of walking behaviour, when used alongside clinical information, may be a useful prognostic clinical tool to identify participants at risk of adverse events.
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